Standard BioTools Inc. has officially completed the sale of its Microfluidics business to ARCHIMED, a private equity firm specializing in healthcare. This transaction, announced on November 3, 2026, signifies a pivotal moment for Standard BioTools as it shifts its operational focus away from microfluidics technology.

The sale is part of a broader strategy by Standard BioTools to streamline its operations and concentrate on core areas within the life sciences sector. The Microfluidics business will now operate under the name Biomark Scientific, aiming to enhance its offerings in genomic workflows.

Background

Standard BioTools Inc. operates in the pharmaceutical preparations industry, specifically under the SIC code 2834. The company trades on the Nasdaq under the ticker symbol LAB. Standard BioTools was previously known as Fluidigm Corp before rebranding in 2022. The company has been active in filing various forms with the SEC, including recent reports on transactions and business updates.

What the Filing Says

According to the SEC filing (accession number 0001140361-26-041711), the joint press release issued by Standard BioTools and ARCHIMED confirms the successful closing of the sale. The press release states, “Biomark Scientific, an innovative microfluidics technology tools provider, will offer versatile and scalable genomic profiling on its flagship Biomark™ platform.”

Impact

This sale may significantly impact Standard BioTools’ operational strategy and financial health, allowing the company to allocate resources more effectively towards its remaining business segments. For ARCHIMED, acquiring the Microfluidics business enhances its portfolio, positioning it to better compete in the life sciences sector.

What's Next

The filing does not say what happens next.